Search alternatives:
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
wt decrease » _ decrease (Expand Search), nn decrease (Expand Search), awd decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 wt » _ wt (Expand Search), 5 ht (Expand Search), i wt (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
wt decrease » _ decrease (Expand Search), nn decrease (Expand Search), awd decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 wt » _ wt (Expand Search), 5 ht (Expand Search), i wt (Expand Search)
-
5661
-
5662
-
5663
-
5664
-
5665
-
5666
-
5667
-
5668
-
5669
The effects of GRK2, GRK2-K220R and β-arrestin 2 on GPR3 WT and ST/A activity and surface localization.
Published 2013“…<p>GPR3-HA WT (<b>A</b>) and ST/A (<b>B</b>) were co-transfected with pcDNA, or GRK2, or GRK2 and β-arrestin-2, or GRK2-K220R, or GRK2-K220R and β-arr-2. …”
-
5670
Immunofluorescence of select extracellular matrix (ECM) components.
Published 2022“…<p>Matched sections from traditional histology (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0269571#pone.0269571.g008" target="_blank">Fig 8</a>) were assessed via immunofluorescence for aggrecan, Collagen Type II, and Collagen Type X. …”
-
5671
-
5672
Effect of CPAF treatment on ear thickness changes over an 18 day course of thrice weekly PMA applications in WT and <i>Ptafr</i>-/- mice.
Published 2014“…For the sake of comparison, the data for the PMA + CPAF treatment in WT mice is included. (mean and SEM; n = 4–5 mice per group). …”
-
5673
-
5674
-
5675
-
5676
-
5677
-
5678
image2_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif
Published 2020“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”
-
5679
presentation1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.pptx
Published 2021“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”
-
5680
image3_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif
Published 2020“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”